# Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients

> **NCT04102956** · PHASE4 · COMPLETED · sponsor: **The Second Hospital of Hebei Medical University** · enrollment: 80 (actual)

## Conditions studied

- Stroke, Acute

## Interventions

- **DRUG:** Kallikrein

## Key facts

- **NCT ID:** NCT04102956
- **Lead sponsor:** The Second Hospital of Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-08-25
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102956, "Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04102956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*